Hours to days
GH and IGF-1 changes measured after dosing in Phase 1.
Protocol / Research Dosing Guide
CJC-1295 with DAC Dosage Guide: Research Schedule and Safety
An evidence-organized guide separating early human pharmacology of long-acting CJC-1295 from community schedules and vial calculations.
Last reviewed September 15, 202621 minute readResearch information only
Level 3 — Early human pharmacologyLong-acting DAC formNot FDA approved
CJC-1295 with DAC Quick Start
CJC-1295 with DAC is a long-acting GHRH analogue engineered to bind albumin. Small human studies measured prolonged GH and IGF-1 responses, but development did not establish an approved indication or general regimen.
Why researchers care
Growth-hormone and IGF-1 pharmacology
Class
Albumin-binding GHRH analogue
Route reported
Subcutaneous in early human studies
Cycle length
Community cycles reported; not clinically validated
Regulatory status
Investigational development discontinued; not FDA approved
Loading supplier information
CJC-1295 with DAC Dosing Protocol and Schedule
The source reports 500–1,000 mcg weekly initially and 1–2 mg weekly later. These are community planning figures, not the weight-based doses used in the early trials.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Weeks 1–2 | 500–1,000 mcg once weekly | Community reported |
| Weeks 3–8 | 1,000 mcg once weekly | Community reported |
| Weeks 3–12 | 2,000 mcg weekly or 1 mg twice weekly | Community reported |
| Phase 2 | Up to 240 mcg/kg/week | Trial parameter only |
The long half-life, trial doses, and community schedules must remain separate. No approved cycle or rest period exists.
CJC-1295 with DAC Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
CJC-1295 with DAC Reconstitution Calculator
Vial-format concentration math
Concentration
2.5 mg/mL
Draw volume
0.2 mL
U-100 units
20
Mathematical draws
10
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take CJC-1295 with DAC: Morning or Night?
Weekly timing
Community schedules use once-weekly or split-weekly administration.
Morning or evening
No human study establishes a superior time.
Steady state
Multi-dose research reported accumulation over several weeks.
Missed amount
No approved missed-dose procedure exists.
CJC-1295 with DAC Route Comparison
| Route | Evidence context | Boundary |
|---|---|---|
| Subcutaneous | Phase 1 and discontinued Phase 2 research | Investigational |
| Oral or nasal | Not established | No validated exposure |
| No-DAC form | Different molecule and PK | Not interchangeable |
| Vendor vial | Research-use listing | Not clinical-trial material |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
CJC-1295 with DAC Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Approximately 5.8–8.1 days | Early human pharmacology |
| GH response | Elevated for at least six days after one dose | Phase 1 finding |
| IGF-1 response | Elevated for about 9–11 days | Phase 1 finding |
| Steady state | About three to four weeks is estimated | Not an approved-use specification |
CJC-1295 with DAC Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 30–60 mcg/kg | Single-dose cohorts | Human Phase 1 | Study design |
| Subcutaneous | 20–30 mcg/kg | Weekly repeated doses | Human Phase 1 | Study design |
| Subcutaneous | 500–1,000 mcg | Once weekly | Community report | No |
| Subcutaneous | 1–2 mg | Weekly | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
CJC-1295 with DAC Reconstitution Guide
Concentration: 2.5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.5 mg | 0.2 mL | 20 units |
| 1 mg | 0.4 mL | 40 units |
| 1.5 mg | 0.6 mL | 60 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How CJC-1295 with DAC Works
GHRH-receptor agonism
Stimulates pituitary GH release through the GHRH receptor.
CJC-1295 with DAC Human Trials and FDA Status
Current status · verified September 15, 2026
Investigational development discontinued; not FDA approved
- A randomized Phase 1 study in healthy adults assessed single and repeated subcutaneous doses.
- Single doses increased mean GH and IGF-1 for multiple days in that controlled pharmacology setting.
- A companion analysis found pulsatile GH secretion persisted during continuous exposure.
- The 192-person HIV-lipodystrophy Phase 2 program was halted after a participant myocardial infarction; the treating physician attributed it to pre-existing coronary disease.
- Development did not produce an approved indication.
Who Should Avoid CJC-1295 with DAC?
This is an evidence-gap and precaution list, not an approved prescribing label.
Active or recent cancer
GH and IGF-1 signaling concern
Significant cardiovascular disease
Development-program safety history
Uncontrolled glucose disorder
GH-axis metabolic effects
Pregnancy or breastfeeding
No established safety
Pituitary or acromegaly disorder
Pathway-specific concern
Tested athletes
GH-releasing factors are prohibited
CJC-1295 with DAC Side Effects, Risks and Safety
Injection-site reactionsHuman trial reported
Important limitation: Pain, redness, swelling, or induration.
Flushing, headache, or nauseaHuman trial reported
Important limitation: Often transient.
Water retention or paresthesiaReported
Important limitation: Potential GH-axis effects.
Cardiovascular eventPhase 2 history
Important limitation: Causality was judged unrelated but program halted.
Glucose effectsPotential pathway risk
Important limitation: Long-term data limited.
Multi-year safetyNot established
Important limitation: Development discontinued.
CJC-1295 with DAC Timeline and Monitoring
About one week
Reported half-life range supports prolonged exposure.
Three to four weeks
Estimated accumulation period in repeated-dose research.
Rest period
Community-reported only; no validated restart criteria.
CJC-1295 with DAC Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| GH secretion | Early human pharmacology | Measured increase | Surrogate endpoint |
| IGF-1 concentration | Early human pharmacology | Measured sustained increase | Surrogate endpoint |
| Body composition | Not established | Phase 2 program incomplete | No approved claim |
| Anti-aging or performance | Not established | Community marketing | No efficacy trial |
CJC-1295 with DAC Storage and Handling
Unreconstituted vial
No independently verified commercial-vial stability duration was identified.
Prepared vial
Community refrigerated-use windows are not product-specific stability studies.
Clinical-trial material
Trial handling cannot be assigned to current vendor vials.
Appearance
Cloudiness, discoloration, or particles require qualified product review.
CJC-1295 with DAC Troubleshooting
Weekly and daily schedules conflict
Confirm whether the molecule has DAC; the forms are not interchangeable.
Units look wrong
Recheck vial mg, liquid mL, target mg, and U-100 conversion.
Hormone changes are presented as outcomes
GH and IGF-1 are surrogate markers, not proven clinical benefit.
Product testing is pending
Do not describe it as batch verified.
A scheduled amount is missed
No approved missed-dose procedure exists.
CJC-1295 with DAC Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| CJC-1295 with DAC | Long-acting GHRH analogue | Early human PK/PD | Not approved |
| CJC-1295 without DAC | Short-acting Mod GRF(1-29) | No direct protocol-scale trial | Not approved |
| Tesamorelin | GHRH analogue | Approved for a narrow HIV indication | Different product |
| Ipamorelin | Ghrelin-receptor agonist | Different pathway | Not approved |
CJC-1295 with DAC Frequently Asked Questions
What does DAC mean?
Drug Affinity Complex, an albumin-binding modification.
Is it the same as no-DAC CJC-1295?
No.
What is its reported half-life?
Approximately 5.8–8.1 days in early human research.
Does it have human studies?
Yes, small early pharmacology studies and a halted Phase 2 program.
Is it FDA approved?
No.
Are community weekly amounts validated?
No.
Did studies prove anti-aging benefits?
No.
Is a rest period established?
No.
What happened in Phase 2?
The program halted after a participant death judged related to pre-existing disease.
What does the calculator do?
It performs concentration and volume arithmetic only.
Sources and Research
Coverage source
1. CJC-1295 with DAC protocol coverage source
Community schedule and evidence overview; not an approved label.
Open direct sourceHuman research
2. Prolonged GH and IGF-1 stimulation by CJC-1295
Controlled early human pharmacokinetic and pharmacodynamic study.
Open direct sourceHuman research
3. Pulsatile GH secretion during CJC-1295 exposure
Companion human pharmacology analysis.
Open direct sourceTrial registry
4. NCT00267527
Discontinued HIV-lipodystrophy Phase 2 registry record.
Open direct sourceMissing information flagged for review
- Approved indication: Not established
- Validated community schedule: Not established
- Clinical outcome efficacy: Not established
- Validated cycle and rest period: Not established
- Current product bioequivalence: Not established
- Product-specific stability: Not established
- Multi-year safety: Not established